Cryogenic Drug Packaging Market
Cryogenic Drug Packaging Market (Product Type: Cryogenic Vials & Tubes, Insulated Shippers & Containers, Cryo-Boxes & Canisters, Dewars & Tanks and Others; Material: Plastic, Glass, Stainless Steel and Composite/Multi-layer Insulation; End-user: Pharmaceutical & Biotechnology Companies, Hospitals & Clinics, Research Institutes & Biobanks and Others) – Global Industry Analysis, Shares, Growth, Trends and Forecast 2021-2036
Categories:
All, Chemicals and Materials, Healthcare and Life Sciences
| Format: PDF/PPT/Excel
| Product ID:
4703
| Report Version:
July 2026
Market Snappshot
- Market Size in 2025: $US 2.38 Bn
- Forecast Market by 2036: $US 6.95 Bn
- CAGR for the Period 2026-2036: 9.5%
- Top Region in Terms of Market Share: North America (41.2%)
- Key Players: Thermo Fisher Scientific Inc., Avantor Inc., Azenta Life Sciences, Cytiva, Corning Incorporated, DWK Life Sciences, Nipro Corporation, BioLife Solutions Inc. and Others
Analyst Viewpoint:
Cryogenic Drug Packaging Market is being reshaped by one simple fact: more of the drug pipeline needs deep-freeze storage than it used to. Cell and gene therapies, mRNA platforms and monoclonal antibodies are pushing packaging requirements well below what a standard refrigerated shipper can handle, often down to -150°C or colder. That’s turning cryogenic vials, dewars and insulated shippers from a specialty niche into a mainstream requirement for a growing share of the biopharma pipeline. Growth is concentrated where biologics manufacturing is heaviest. North America and parts of Europe lead on validated, regulatory-compliant systems, while China and India are scaling capacity fast to support both domestic biologics output and export-driven clinical trial material. Cost remains the sticking point. Cryogenic-grade packaging runs well above standard cold chain pricing, and that premium is limiting adoption to high-value biologics and vaccines for now. Even so, the pipeline shift toward temperature-sensitive advanced therapies means this segment keeps outpacing broader pharmaceutical packaging growth.
Cryogenic Drug Packaging Market Overview:
The Cryogenic Drug Packaging Market covers vials, insulated shippers, dewars, cryo-boxes and related systems built to hold pharmaceutical products at ultra-low temperatures, typically below -80°C and in some cases as cold as -150°C to -196°C. Biologics, cell and gene therapies, and mRNA-based vaccines are the primary drivers, since these products lose potency quickly outside narrow temperature bands.
Research shows biopharmaceutical companies are the largest end-use segment, reflecting the sheer number of biologics now moving through clinical trials and commercial distribution that require validated cryogenic handling. Insulated shippers and containers are growing the fastest among product types, as logistics providers look for lighter, more space-efficient designs for long-haul air freight. Vials and tubes remain the most established product category, valued for reliability in both storage and transport of biological materials.
Regulatory pressure is a constant undercurrent here. The FDA’s biologics licensing requirements demand validated proof of thermal stability throughout transit, which makes packaging qualification part of the approval process itself, not an afterthought. That’s pushing packaging providers toward IoT-enabled monitoring and real-time tracking, on top of the insulation and materials work that used to define this category. Investments in dewars, reusable shippers and phase-change materials are expanding accordingly, particularly for the CAR-T, antibody-drug conjugate and mRNA vaccine segments driving the sharpest growth.
Research shows biopharmaceutical companies are the largest end-use segment, reflecting the sheer number of biologics now moving through clinical trials and commercial distribution that require validated cryogenic handling. Insulated shippers and containers are growing the fastest among product types, as logistics providers look for lighter, more space-efficient designs for long-haul air freight. Vials and tubes remain the most established product category, valued for reliability in both storage and transport of biological materials.
Regulatory pressure is a constant undercurrent here. The FDA’s biologics licensing requirements demand validated proof of thermal stability throughout transit, which makes packaging qualification part of the approval process itself, not an afterthought. That’s pushing packaging providers toward IoT-enabled monitoring and real-time tracking, on top of the insulation and materials work that used to define this category. Investments in dewars, reusable shippers and phase-change materials are expanding accordingly, particularly for the CAR-T, antibody-drug conjugate and mRNA vaccine segments driving the sharpest growth.
| Drivers | Rising Biologics and Cell & Gene Therapy Pipeline |
| Tightening Regulatory Requirements for Packaging Validation |
Rising Biologics and Cell & Gene Therapy Pipeline
The single biggest force behind this market is the drug pipeline itself. Biologics now make up a growing share of new drug approvals, and a large majority of them need active cold chain management. Cell and gene therapies, CAR-T treatments and antibody-drug conjugates are the fastest-growing therapeutic categories in development, and most of them require cryogenic conditions well below -80°C for extended periods, not just short-term refrigeration.
mRNA vaccines pushed this trend into the mainstream. The Pfizer-BioNTech and Moderna COVID-19 vaccines needed storage at -70°C to -80°C, and that requirement forced logistics providers and packaging manufacturers to build out cryogenic infrastructure at a scale that didn’t exist a few years earlier. CSafe launched its Multi-Use Dewars in April 2024, purpose-built for cell and gene therapy shipments that need temperatures of -150°C or colder, complete with built-in real-time tracking. HV3 cryogenic shipper by Cryoport was introduced in January 2025 as another cryogenic container to tap into the same high-technology field.
The continuing trend of growing clinical trials, personalized medicines, and investments into biopharmaceuticals’ production are among many factors suggesting a steady need for cryogenic packaging in the coming ten years, and not just a surge driven by the pandemic.
mRNA vaccines pushed this trend into the mainstream. The Pfizer-BioNTech and Moderna COVID-19 vaccines needed storage at -70°C to -80°C, and that requirement forced logistics providers and packaging manufacturers to build out cryogenic infrastructure at a scale that didn’t exist a few years earlier. CSafe launched its Multi-Use Dewars in April 2024, purpose-built for cell and gene therapy shipments that need temperatures of -150°C or colder, complete with built-in real-time tracking. HV3 cryogenic shipper by Cryoport was introduced in January 2025 as another cryogenic container to tap into the same high-technology field.
The continuing trend of growing clinical trials, personalized medicines, and investments into biopharmaceuticals’ production are among many factors suggesting a steady need for cryogenic packaging in the coming ten years, and not just a surge driven by the pandemic.
Tightening Regulatory Requirements for Packaging Validation
Regulation is doing as much to shape this market as the drugs themselves. The FDA requires validated evidence that packaging maintains product stability throughout transit before a biologic can be approved, which means packaging qualification is now baked into the regulatory pathway rather than handled separately afterward. That raises the bar for any supplier trying to enter the cryogenic space, since a shipper or vial has to prove performance under real-world shipping conditions, not just in a lab.
International shipping adds another layer. Hazardous materials rules such as UN3373 for biological substances impose their own packaging and labeling requirements, and meeting both thermal protection standards and hazmat compliance at the same time is a genuine engineering challenge for manufacturers. ISO 13485 for medical device manufacturing and USP for container materials add further validation and documentation steps, which lengthens development cycles for new cryogenic packaging designs.
These compliance demands are, in a roundabout way, good for established suppliers. Companies with the testing infrastructure and regulatory track record to clear these hurdles quickly are pulling ahead of newer entrants who have to build that credibility from scratch, which is part of why the competitive field here stays fairly concentrated at the top.
International shipping adds another layer. Hazardous materials rules such as UN3373 for biological substances impose their own packaging and labeling requirements, and meeting both thermal protection standards and hazmat compliance at the same time is a genuine engineering challenge for manufacturers. ISO 13485 for medical device manufacturing and USP for container materials add further validation and documentation steps, which lengthens development cycles for new cryogenic packaging designs.
These compliance demands are, in a roundabout way, good for established suppliers. Companies with the testing infrastructure and regulatory track record to clear these hurdles quickly are pulling ahead of newer entrants who have to build that credibility from scratch, which is part of why the competitive field here stays fairly concentrated at the top.
Cryogenic Drug Packaging Regional Market Outlook:
North America holds dominant share in the Cryogenic Drug Packaging Market Analysis, with about 41.2% revenue share, due to presence of well-established biologics manufacturers, development of cell and gene therapy pipeline, established biobanks, and regulatory framework of FDA.
Europe represents nearly 28.5% of the market, supported by growing biologics production in Germany, Switzerland, the United Kingdom, France, and the Netherlands. EU investments in advanced therapy medicinal products and expanding pharmaceutical exports continue strengthening demand for Cryogenic Pharmaceutical Packaging.
Asia-Pacific region accounts for roughly 22.3% market share, and the fastest growth rate during the forecast period. Biologics manufacturing, vaccines and contract manufacturing operations in China, Japan, South Korea, India, and Singapore create a promising outlook for Cryogenic Packaging solutions.
Middle East & Africa region accounts for approximately 4.3%, driven by health care development and rise in vaccination infrastructure in the GCC nations along with pharmaceutical manufacturing.
The Latin America region contributes nearly 3.7% market share and is propelled by rising biologics imports and pharmaceutical manufacturing in nations such as Brazil, Mexico, and Argentina.
Europe represents nearly 28.5% of the market, supported by growing biologics production in Germany, Switzerland, the United Kingdom, France, and the Netherlands. EU investments in advanced therapy medicinal products and expanding pharmaceutical exports continue strengthening demand for Cryogenic Pharmaceutical Packaging.
Asia-Pacific region accounts for roughly 22.3% market share, and the fastest growth rate during the forecast period. Biologics manufacturing, vaccines and contract manufacturing operations in China, Japan, South Korea, India, and Singapore create a promising outlook for Cryogenic Packaging solutions.
Middle East & Africa region accounts for approximately 4.3%, driven by health care development and rise in vaccination infrastructure in the GCC nations along with pharmaceutical manufacturing.
The Latin America region contributes nearly 3.7% market share and is propelled by rising biologics imports and pharmaceutical manufacturing in nations such as Brazil, Mexico, and Argentina.
Key Companies in Cryogenic Drug Packaging Market:
The competitive landscape is fairly concentrated, given that there are only a few players who have control over large pharma contracts owing to their tested portfolio of products and existing ties with drug companies. Entry barriers are higher than normal cold chain packaging because cryogenic solutions that cater to pharmaceuticals require thorough testing in order to even qualify for a contract bid.
Latest developments in this industry have been about introducing new products to support advanced therapy products, acquisition of reusable and sustainable packaging solutions, and collaboration that will help improve temperature monitoring during long distance transport.
Key players include Thermo Fisher Scientific Inc., Avantor Inc., Azenta Life Sciences, Cytiva, Corning Incorporated, DWK Life Sciences, Nipro Corporation, BioLife Solutions Inc., Cryoport Inc., Schott AG, Gerresheimer AG, and others.
Latest developments in this industry have been about introducing new products to support advanced therapy products, acquisition of reusable and sustainable packaging solutions, and collaboration that will help improve temperature monitoring during long distance transport.
Key players include Thermo Fisher Scientific Inc., Avantor Inc., Azenta Life Sciences, Cytiva, Corning Incorporated, DWK Life Sciences, Nipro Corporation, BioLife Solutions Inc., Cryoport Inc., Schott AG, Gerresheimer AG, and others.
Key Developments in Cryogenic Drug Packaging Market:
| 1. Cryoport Unveils HV3 Cryogenic Shipping System: In January 2025, Cryoport introduced its Cryoport Express HV3 shipping system, designed for advanced therapies requiring extended ultra-low temperature hold times. |
| 2. CSafe launches Multi-Use Dewars for cell and gene therapies: In April 2024, CSafe launched reusable cryogenic dewars maintaining -150°C or colder, featuring built-in real-time data tracking for the cell and gene therapy market. |
Cryogenic Drug Packaging Market Attributes:
| ATTRIBUTE | DETAILS |
| Market Value, 2025 | $US 2.38 Billion |
| Forecasted Market Value, 2036 | $US 6.95 Billion |
| CAGR (2026-2036) | 9.5% |
| Analysis Period | 2021-2036 |
| Historic Period | 2021-2024 |
| Base Year | 2025 |
| Forecast Period | 2026-2036 |
| Volume Unit | Units |
| Value Unit | $US Billion |
| Market Segmentation | By Product Type
By Material
By End-user
By Region
|
| Companies Profiles |
|
| Customization Request | Available upon request |
1. Introduction
1.1. Report Scope
1.2. Market Segmentations and Definitions
1.3. Geographical Coverage
2. Executive Summary
2.1. Key Facts and Figures
2.2. Trends Impacting the Market
2.3. DatasticsR Growth Opportunity Matrix
3. Market Overview
3.1. Global Cryogenic Drug Packaging Market Analysis and Forecast, 2021-2036
3.1.1. Global Cryogenic Drug Packaging Market Size (Units)
3.1.2. Global Cryogenic Drug Packaging Market Size ($US Bn)
3.2. Supply-side and Demand-side Trends
3.3. Technology Roadmap and Developments
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Porter’s Five Forces Analysis
3.6. PESTL Analysis
3.7. Industry SWOT Analysis
3.8. Regulatory Landscape
3.9. Value Chain Analysis
3.9.1. List of Raw Materials Suppliers
3.9.2. List of Packaging Companies
3.9.3. List of Dealers / Distributors
3.9.4. List of Importers / Exporters
3.9.5. List of Potential Customers
3.10. Impact of Current Geopolitical Scenario on the Market
4. Technical Analysis
4.1. Technical Specification Analysis
4.2. Details of Production Process
4.3. Technology Adoption and Emerging Technologies
4.4. R&D Trends and Patents Landscape
4.5. Cost Structure and Profitability Analysis
5. Global Cryogenic Drug Packaging Production (Units) Output, by Region, 2025
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Latin America
5.5. Middle East and Africa
6. Import-export Analysis Volume (Units) and Value ($US Bn), by Key Country, 2021-2025
7. Price Trend Analysis and Forecasting ($US/ Unit), 2021-2036
7.1. Price Trend Analysis and Forecasting, by Product Type
7.2. Price Trend Analysis and Forecasting, by Material
7.3. Price Trend Analysis and Forecasting, by Region
8. Global Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
9. Global Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
10. Global Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
11. Global Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Region, 2021-2036
12. North America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
13. North America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
14. North America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
15. U.S. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
16. U.S. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
17. U.S. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
18. Canada Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
19. Canada Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
20. Canada Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
21. Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
22. Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
23. Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
24. Germany Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
25. Germany Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
26. Germany Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
27. U.K. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
28. U.K. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
29. U.K. Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
30. France Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
31. France Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
32. France Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
33. Italy Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
34. Italy Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
35. Italy Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
36. Spain Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
37. Spain Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
38. Spain Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
39. Russia & CIS Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
40. Russia & CIS Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
41. Russia & CIS Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
42. Rest of Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
43. Rest of Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
44. Rest of Europe Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
45. Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
46. Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
47. Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
48. China Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
49. China Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
50. China Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
51. India Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
52. India Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
53. India Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
54. Japan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
55. Japan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
56. Japan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
57. South Korea Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
58. South Korea Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
59. South Korea Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
60. Taiwan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
61. Taiwan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
62. Taiwan Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
63. Australia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
64. Australia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
65. Australia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
66. ASEAN Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
67. ASEAN Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
68. ASEAN Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
69. Rest of Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
70. Rest of Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
71. Rest of Asia Pacific Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
72. Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
73. Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
74. Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
75. Brazil Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
76. Brazil Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
77. Brazil Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
78. Mexico Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
79. Mexico Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
80. Mexico Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
81. Argentina Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
82. Argentina Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
83. Argentina Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
84. Rest of Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
85. Rest of Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
86. Rest of Latin America Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
87. Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
88. Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
89. Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
90. Saudi Arabia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
91. Saudi Arabia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
92. Saudi Arabia Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
93. UAE Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
94. UAE Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
95. UAE Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
96. South Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
97. South Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
98. South Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
99. Rest of Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Product Type, 2021-2036
100. Rest of Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by Material, 2021-2036
101. Rest of Middle East & Africa Cryogenic Drug Packaging Market Analysis and Forecasting (Units) ($US Bn), by End-user, 2021-2036
102. Competition Landscape
102.1. Market Share Analysis (%), by Company, 2025
102.2. Competitive Benchmarking
102.3. Company Profiles
102.3.1. Thermo Fisher Scientific Inc.
102.3.1.1. Company Overview
102.3.1.2. Business Portfolio
102.3.1.3. Financials
102.3.1.4. Geographical Footprint
102.3.1.5. SWOT Analysis
102.3.1.6. Recent Developments and Strategies
102.3.2. Avantor Inc.
102.3.2.1. Company Overview
102.3.2.2. Business Portfolio
102.3.2.3. Financials
102.3.2.4. Geographical Footprint
102.3.2.5. SWOT Analysis
102.3.2.6. Recent Developments and Strategies
102.3.3. Azenta Life Sciences
102.3.3.1. Company Overview
102.3.3.2. Business Portfolio
102.3.3.3. Financials
102.3.3.4. Geographical Footprint
102.3.3.5. SWOT Analysis
102.3.3.6. Recent Developments and Strategies
102.3.4. Cytiva
102.3.4.1. Company Overview
102.3.4.2. Business Portfolio
102.3.4.3. Financials
102.3.4.4. Geographical Footprint
102.3.4.5. SWOT Analysis
102.3.4.6. Recent Developments and Strategies
102.3.5. Corning Incorporated
102.3.5.1. Company Overview
102.3.5.2. Business Portfolio
102.3.5.3. Financials
102.3.5.4. Geographical Footprint
102.3.5.5. SWOT Analysis
102.3.5.6. Recent Developments and Strategies
102.3.6. DWK Life Sciences
102.3.6.1. Company Overview
102.3.6.2. Business Portfolio
102.3.6.3. Financials
102.3.6.4. Geographical Footprint
102.3.6.5. SWOT Analysis
102.3.6.6. Recent Developments and Strategies
102.3.7. Nipro Corporation
102.3.7.1. Company Overview
102.3.7.2. Business Portfolio
102.3.7.3. Financials
102.3.7.4. Geographical Footprint
102.3.7.5. SWOT Analysis
102.3.7.6. Recent Developments and Strategies
102.3.8. BioLife Solutions Inc.
102.3.8.1. Company Overview
102.3.8.2. Business Portfolio
102.3.8.3. Financials
102.3.8.4. Geographical Footprint
102.3.8.5. SWOT Analysis
102.3.8.6. Recent Developments and Strategies
102.3.9. Cryoport Inc.
102.3.9.1. Company Overview
102.3.9.2. Business Portfolio
102.3.9.3. Financials
102.3.9.4. Geographical Footprint
102.3.9.5. SWOT Analysis
102.3.9.6. Recent Developments and Strategies
102.3.10. Schott AG
102.3.10.1. Company Overview
102.3.10.2. Business Portfolio
102.3.10.3. Financials
102.3.10.4. Geographical Footprint
102.3.10.5. SWOT Analysis
102.3.10.6. Recent Developments and Strategies
102.3.11. Gerresheimer AG
102.3.11.1. Company Overview
102.3.11.2. Business Portfolio
102.3.11.3. Financials
102.3.11.4. Geographical Footprint
102.3.11.5. SWOT Analysis
102.3.11.6. Recent Developments and Strategies
102.3.12. Others
103. Appendix
- Get Started -
Get insights that lead to new growth opportunities
- Talk to Experts -
Get answers to your queries on this report from our experts
Frequently Asked Questions
The global Cryogenic Drug Packaging market in 2025 was $US 2.38 Billion.
The global Cryogenic Drug Packaging market will be $US 6.95 Billion by 2036.
The expected growth rate (CAGR%) of the global Cryogenic Drug Packaging market is 9.5% for the period 2026-2036.
Rising Biologics and Cell & Gene Therapy Pipeline and Tightening Regulatory Requirements for Packaging Validation.
Cryogenic Vials & Tubes was the largest segment in product type holding more than 40% share among all in Cryogenic Drug Packaging Market in 2025.
North America was the leading regions for Cryogenic Drug Packaging holding 41.2% of the global market in 2025.
Thermo Fisher Scientific Inc., Avantor Inc., Azenta Life Sciences, Cytiva, Corning Incorporated, DWK Life Sciences, Nipro Corporation, BioLife Solutions Inc., Cryoport Inc., Schott AG, Gerresheimer AG, and Others.
